|
8941 |
Safety of DW-MSC infusion in patients with low clinical risk COVID-19 infection: a randomized, double-blind, placebo-controlled trial
Enthalten in Stem cell research & therapy Bd. 13, 1.4.2022, Nr. 1, date:12.2022: 1-10
|
|
|
|
8942 |
Safety of phosphatidylserine containing omega-3 fatty acids in non-demented elderly: a double-blind placebo-controlled trial followed by an open-label extension
Enthalten in BMC neurology Bd. 11, 28.6.2011, Nr. 1, date:12.2011: 1-10
|
|
|
|
8943 |
Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hocanalysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial
Enthalten in Critical care Bd. 11, 8.8.2007, Nr. 4, date:8.2007: 1-8
|
|
|
|
8944 |
Safety of sildenafil in premature infants with severe bronchopulmonary dysplasia (SILDI-SAFE): a multicenter, randomized, placebo-controlled, sequential dose-escalating, double-masked, safety study
Enthalten in BMC pediatrics Bd. 20, 14.12.2020, Nr. 1, date:12.2020: 1-9
|
|
|
|
8945 |
Safety profile of darolutamide versus placebo: a systematic review and meta-analysis
Enthalten in Prostate cancer and prostatic diseases Bd. 27, 14.12.2023, Nr. 3, date:9.2024: 385-392
|
|
|
|
8946 |
Safety, effectiveness, and economic evaluation of an herbal medicine, Ukgansangajinpibanha granule, in children with autism spectrum disorder: a study protocol for a prospective, multicenter, randomized, double-blinded, placebo-controlled, parallel-group clinical trial
Enthalten in Trials Bd. 20, 15.7.2019, Nr. 1, date:12.2019: 1-11
|
|
|
|
8947 |
Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons
Enthalten in BMC infectious diseases Bd. 10, 17.3.2010, Nr. 1, date:12.2010: 1-14
|
|
|
|
8948 |
Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial
Enthalten in Nature Communications Bd. 16, 4.3.2025, Nr. 1, date:12.2025: 1-16
|
|
|
|
8949 |
Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial
Enthalten in Nature medicine Bd. 28, 27.10.2022, Nr. 12, date:12.2022: 2611-2621
|
|
|
|
8950 |
Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study
Enthalten in Dermatology and therapy Bd. 13, 5.9.2023, Nr. 10, date:10.2023: 2357-2373
|
|
Administration
